Cost of Apolipoprotein B (Apo-B) Testing in the United States
In the United States, apo-B testing typically costs between $25-75 per test when ordered through commercial laboratories, though the exact cost varies by laboratory, insurance coverage, and geographic location.
Key Cost Considerations
Insurance Coverage and Out-of-Pocket Expenses
The available evidence from Canadian guidelines provides important context: apo-B is available as an insured laboratory test in all Canadian provinces except Ontario, while non-HDL-C is routinely reported at no additional cost 1. This Canadian model demonstrates that apo-B testing can be integrated into healthcare systems as a covered benefit.
In the U.S., commercial insurance coverage varies significantly:
- Most commercial insurance plans cover apo-B testing when medically indicated
- Patient out-of-pocket costs are typically minimal ($0-12 median) for most insurance types except consumer-driven health plans 2
- The test is generally less expensive than comprehensive genomic or biomarker panels
Comparative Cost Analysis
The 2011 AHA guidelines explicitly noted that apo-B assays have "higher cost than for non-HDL-C" 3, which was cited as one reason ATP III guidelines favored non-HDL-C. However, this cost differential has narrowed considerably since 2011 as apo-B assays have become more standardized and widely available.
The Canadian guidelines emphasize that "non-HDL-C is currently a more practical choice because it incurs no additional expense to the patient or health care system" 1, since non-HDL-C is simply calculated from total cholesterol minus HDL-C from a standard lipid panel.
Clinical Value Relative to Cost
When Apo-B Testing Adds Value
Despite the additional cost compared to calculated non-HDL-C, apo-B measurement is particularly valuable in specific clinical scenarios 4, 5:
- Patients with triglycerides ≥150 mg/dL where LDL-C calculations become unreliable
- Patients with diabetes or metabolic syndrome where lipid discordance is common
- Individuals with established ASCVD requiring precise risk assessment
- Cases of discordance between LDL-C and non-HDL-C (affecting 8-23% of patients) 1
The 2017 AACE guidelines recommend apo-B measurement specifically for "at-risk individuals (TG ≥150, HDL-C <40, prior ASCVD event, T2DM, and/or insulin resistance syndrome)" 4.
Cost-Effectiveness Perspective
The lifetime median cost of all biomarker testing in cancer patients was only $394-462 2, suggesting that individual biomarker tests like apo-B represent a small fraction of overall healthcare costs. When considering that apo-B provides superior cardiovascular risk prediction compared to LDL-C 1, 6, the incremental cost is justified in appropriate clinical contexts.
Practical Recommendations
When to Order Apo-B vs. Use Non-HDL-C
- Use non-HDL-C (no additional cost) for routine screening and when triglycerides <150 mg/dL
- Order apo-B testing when:
- Triglycerides ≥150 mg/dL
- Suspected lipid discordance
- Diabetes with complex lipid profiles
- Monitoring adequacy of lipid-lowering therapy in high-risk patients
- Family history of premature ASCVD with unclear lipid phenotype
Common Pitfalls
- Don't reflexively order apo-B on all patients – non-HDL-C is adequate for most routine assessments
- Don't let cost alone determine testing – in high-risk patients where precise measurement matters, the $25-75 cost is negligible compared to potential cardiovascular events
- Verify insurance coverage beforehand for patients with high-deductible plans to avoid surprise bills
The evidence supports that apo-B testing is relatively inexpensive and should not be a barrier to access when clinically indicated 2, particularly given its superior predictive value for ASCVD risk in specific populations 1, 7.